"Your healthcare team may recommend gradually reducing your dose under medical supervision rather than stopping abruptly." During the tapering process, your healthcare provider will monitor your response and may adjust your plan as needed
When examining a composite cardio outcomes endpoint (death from CV disease, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for unstable angina), the ELIXA trial suggested that GLP-1s did not increase cardiovascular event risk (hazard ratio of 1.02)
FOR DECREASED APPETITE SOURCE: DailyMed
The pre-filled pen devices are specifically engineered to deliver accurate doses and include safety features to prevent dosing errors
To effectively lose excess weight, patients need to be able to maintain a calorie-deficient diet while continuing to exercise so that the metabolism is forced to start using the stored excess fat to burn for energy instead of relying on continuously consumed calories to directly use for energy
If you have any questions or concerns about your medication, you can contact our customer support team